These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2896509

  • 1. General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st communication: effects on the central nervous system.
    Saito T, Fukuda T, Sukamoto T, Yoshidomi M, Morimoto Y, Shimohara K, Ito K.
    Arzneimittelforschung; 1988 Jan; 38(1):66-9. PubMed ID: 2896509
    [Abstract] [Full Text] [Related]

  • 2. General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 2nd communication: Effects on the circulation and the other systems.
    Saito T, Fukuda T, Tajima S, Sukamoto T, Yamashita A, Kanazawa T, Morimoto Y, Shimohara K, Nishimura N, Yokota K.
    Arzneimittelforschung; 1988 Feb; 38(2):267-72. PubMed ID: 2897196
    [Abstract] [Full Text] [Related]

  • 3. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I, Kihara T, Nakamura S, Hattori Y, Hatta M, Kitakaze Y, Takahama K, Hashimoto Y, Miyata T, Ishihara T.
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [Abstract] [Full Text] [Related]

  • 4. Effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimida zole difumarate (KB-2413), a new antiallergic, on chemical mediators.
    Fukuda T, Morimoto Y, Iemura R, Kawashima T, Tsukamoto G, Ito K.
    Arzneimittelforschung; 1984 Oct; 34(7):801-5. PubMed ID: 6149754
    [Abstract] [Full Text] [Related]

  • 5. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
    Kurumiya S, Miura Y, Nakatsuji K, Dodo M, Hori M, Ito T.
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
    [Abstract] [Full Text] [Related]

  • 6. Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413).
    Fukuda T, Saito T, Tajima S, Shimohara K, Ito K.
    Arzneimittelforschung; 1984 Feb; 34(7):805-10. PubMed ID: 6208915
    [Abstract] [Full Text] [Related]

  • 7. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G, Morimoto S, Shiomi M.
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [Abstract] [Full Text] [Related]

  • 8. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system.
    Kaneko T, Kitahara A, Ozaki S, Takizawa K, Yamatsu K.
    Arzneimittelforschung; 1981 Jun; 31(8):1206-12. PubMed ID: 6117290
    [Abstract] [Full Text] [Related]

  • 9. Antiasthmatic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413), a new antiallergic.
    Fukuda T, Saito T, Ito K.
    Arzneimittelforschung; 1984 Jun; 34(7):811-5. PubMed ID: 6149755
    [Abstract] [Full Text] [Related]

  • 10. [General pharmacology of 6-amino-2-fluoromethyl-3-(o-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. I. Effects on the central nervous system (author's transl)].
    Ochiai T, Yamamura M, Kudo Y, Ishida R.
    Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):347-57. PubMed ID: 7327455
    [Abstract] [Full Text] [Related]

  • 11. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 12. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
    Yamamoto S, Takemori E, Hasegawa Y, Nakao K, Inukai T, Nomura M, Morino K, Tsuchiyama M, Hasegawa K, Ikeda H.
    Arzneimittelforschung; 1991 Jun; 41(6):602-7. PubMed ID: 1930347
    [Abstract] [Full Text] [Related]

  • 13. Central effect of the potent long-acting H1-antihistamine levocabastine.
    Tasaka K, Kamei C, Tsujimoto S, Yoshida T, Aoki I.
    Arzneimittelforschung; 1990 Dec; 40(12):1295-9. PubMed ID: 1982750
    [Abstract] [Full Text] [Related]

  • 14. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T, Sakaya S, Hoshino T, Umetsu T, Hirano T, Nishio S.
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [Abstract] [Full Text] [Related]

  • 15. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M, Yajima M, Nishimura T, Ikeda H, Nishimori T.
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [Abstract] [Full Text] [Related]

  • 16. Comparative study of various H1-blockers on neuropharmacological and behavioral effects including 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413), a new antiallergic agent.
    Tasaka K, Kamei C, Katayama S, Kitazumi K, Akahori H, Hokonohara T.
    Arch Int Pharmacodyn Ther; 1986 Apr; 280(2):275-91. PubMed ID: 2872864
    [Abstract] [Full Text] [Related]

  • 17. Influence of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413), a new antiallergic, on ciliary movement.
    Fukuda T, Saito T, Yoshidomi M, Ito K.
    Arzneimittelforschung; 1984 Apr; 34(7):816-8. PubMed ID: 6149756
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacological study of mequitazine (LM-209) (III). Action on the central nervous system (author's transl)].
    Fujimura H, Tsurumi K, Yanagihara M, Hiramatsu Y, Tamura Y, Shimizu Y, Hojo M, Yoshida Y, Serizawa I.
    Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):249-60. PubMed ID: 6120125
    [Abstract] [Full Text] [Related]

  • 19. General pharmacological properties of muroctasin.
    Kojima H, Hirohashi M, Kasai Y, Takasuna K, Fukumoto C, Akashi A.
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [Abstract] [Full Text] [Related]

  • 20. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S, Toba Y, Suzuki S, Ninomiya S, Umezato M, Hiyama T.
    Arzneimittelforschung; 1985 Jul; 35(7A):1157-62. PubMed ID: 4074429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.